ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Abstract Number: 1205

OARSI Initiative to Develop Classification Criteria for Early-Stage Symptomatic Knee OA (EsSKOA): What Should Be Considered in the Differential Diagnosis of EsSKOA?
Abstract Number: 0294

Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample
Abstract Number: 0864

Obesity Subtypes and Trajectories of Functional Change After 7-years of Follow-up: The Multicenter Osteoarthritis (MOST) Study
Abstract Number: 0483

Obesity, Prednisone Use, and Patient-Reported Outcomes Are Predictors of Becoming Difficult-to-Treat in an RA Population Treated with a First-Line Biologic DMARD
Abstract Number: 0659

Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial
Abstract Number: 1427

Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study
Abstract Number: 1224

Occupational Stress and Fibromyalgia Among Healthcare Professionals in Abu Dhabi Region, United Arab Emirates: A Cross-sectional Study
Abstract Number: 2035

Older Age and Higher Erythrocyte Sedimentation Rate Are Associated with Increased Disease Burden at Diagnosis in a Cohort of IgG4-Related Disease Patients
Abstract Number: 1387

Olokizumab Effect on Chronic Pain in Rheumatoid Arthritis: Results of the Observational Study
Abstract Number: 1386

Olokizumab in Real Clinical Practice: Efficacy and Safety
Abstract Number: 0405

Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
Abstract Number: 0739

One Year Outcomes in Those with Isolated PMR Recruited via a Fast Track PMR Clinic
Abstract Number: 1390

One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)
Abstract Number: 1694

One-Year Survival Following Single versus Double Lung Transplantation in Adults with Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Disease: A Nationwide Cohort Study
Abstract Number: 0367

Opinions from Rheumatoid Arthritis Patients and Providers on Discontinuing Methotrexate in Stable Disease
Abstract Number: 1868

Opioid Prescription Rates in Patients with Radiographic Axial Spondyloarthritis in the US Between 2008-2021: A Joinpoint Regression Analysis
Abstract Number: 2683

Optical Coherence Angiography: A Non-invasive, Safe Method for Assessing the Systemic Sclerosis Related Vasculopathy Beyond Nailfold Capillaries
Abstract Number: 1210

Optimal Definitions of Worsening Cartilage Using Sequential MRI OsteoArthritis Knee Scores (MOAKS)
Abstract Number: 1241

Optimizing Communication of Methotrexate (MTX) Side Effects: A Patient-Centered Approach Focused on Learning Styles and Preferred Language
Abstract Number: 1075

Optimizing Herpes Zoster Vaccination in Rheumatoid Arthritis Patients Ages 18-49 Years: A Quality Improvement Approach
Abstract Number: 2191

Optimizing Inpatient Kawasaki Disease Care
Abstract Number: 0791

Optimizing Knee Osteoarthritis Treatment with the Precision Medicine Approach in a Clinical Trial Dataset
Abstract Number: 1947

Optimizing Osteoarthritis Care Through Clinical and Community Partnership: Results of an Exploratory Trial
Abstract Number: 0827

Oral Corticosteroid-Sparing Effects of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Results up to 7.4 Years from the Long-Term Access Programme
Abstract Number: 0535

Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients
Abstract Number: 1641

Orbital MRI as a Promising Approach for the Diagnosis of Giant Cell Arteritis in Case of Anterior Ischemic Optical Neuropathy or Central Retinal Artery Occlusion
Abstract Number: 2485

Orbital Pseudotumor in Granulomatosis with Polyangiitis. Interim Analysis of Clinical Outcomes from a European Collaborative Observational Study
Abstract Number: 1417

Organ-Specific Autoimmune Involvement in Primary Sjögren’s Disease
Abstract Number: 1653

Osteoarthritis Drives Inflammatory Imprinting of Synovial Fibroblasts, Exacerbating Gouty Arthritis Through m6A Modification of S100A4
Abstract Number: 1730

Osteoarthritis Is a Risk Factor for Inflammatory Arthritis in Cancer Patients Treated with Immune Checkpoint Inhibitors
Abstract Number: 0400

Osteoclastogenesis from Peripheral Blood Mononuclear Cells in Children with Chronic Nonbacterial Osteomyelitis Are Similar to Those from Healthy Children
Abstract Number: 1033

Osteoporosis and Cardiovascular Disease: Mortality Trends Among Adults in the United States from 1999 to 2020
Abstract Number: 1084

Osteoporosis and Osteopenia Diagnosed by Dual-Energy X-Ray Absorptiometry Are Not Increased in Patients with Gout
Abstract Number: 2197

Outcome Measures for the Assessment of Cutaneous and Musculoskeletal Manifestations of Juvenile Systemic Sclerosis: An International Collaborative Scoping Review and Survey of Current Practice
Abstract Number: 1499

Outcome of Newly Onset SLE with Neuropsychiatric Symptoms and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Abstract Number: 2187

Outcomes Following Tonsillectomy in Children with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome
Abstract Number: 2220

Outcomes in Seronegative Rheumatoid Arthritis and Undifferentiated Arthritis
Abstract Number: 0716

Outcomes of COVID-19 in Patients with ANCA-Associated Vasculitis (AAV)
Abstract Number: 0708

Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Abstract Number: 0253

Outcomes of Respiratory Syncytial Virus Infection in Patients with Systemic Autoimmune Rheumatic Diseases
Abstract Number: 2383

Outcomes of Systemic Lupus Erythematosus Hospitalizations: Insights from a Multinational Tertiary Center Experience
Abstract Number: 0093

Overexpression of Epidermal Ifnk Promotes Systemic CD8+ T Cell Maturation After UV-exposure
Abstract Number: 1592

Overlapping Forms of Eosinophilic Granulomatosis with Polyangiitis and Granulomatosis with Polyangiitis: Presentation, Management and Outcomes
Abstract Number: 1580

Overt Polyautoimmunity and Its Risk Factors in a Multicenter Cohort of Systemic Sclerosis Patients
Abstract Number: 2042

Overview of Lung Manifestations in Sarcoidosis and Various Treatment Approaches at a University Center
Abstract Number: 0438

Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].